DCM
CBMG

Driehaus Capital Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Driehaus Capital Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-48,522
Closed -$1.53M – 610
2015
Q1 		$1.53M Buy
+48,522
New +$1.31M 0.05% 369

Other funds holding CBMG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Driehaus Capital Management's CBMG Position: Q2 2015 in Review

Driehaus Capital Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2015, closing a stake of 48,522 shares — an estimated $1.53M sold.

Driehaus Capital Management first reported a position in CBMG in Q1 2015 and held it in 1 quarter. The position peaked at $1.53M in Q1 2015. 45 funds tracked by Wall St. Rank hold CBMG as of Q2 2015.

  • Driehaus Capital Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2015 after selling out during the quarter.
  • Driehaus Capital Management sold 48,522 Cellular Biomedicine Group, Inc. shares in Q2 2015, an estimated $1.53M.
  • Driehaus Capital Management first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 1 quarter.
  • Driehaus Capital Management's Cellular Biomedicine Group, Inc. position peaked at $1.53M in Q1 2015.
  • 45 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2015.

Based on Driehaus Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.